Skip to main content
. 2017 Jul 19;6(7):e005428. doi: 10.1161/JAHA.116.005428

Figure 1.

Figure 1

Proportion of propensity‐matched cohort of patients in the Stockholm Creatinine Measurements (SCREAM) cohort initiating or β‐blocker therapy (light gray; N=20 186) or angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker therapy (dark gray; N=20 186) with (A) potassium >5 mmol/L and (B) potassium >5.5 mmol/L during the first year on therapy. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.